Succinate Fuels CCR4+ Treg Expansion and Immune Escape in Aging Ovarian Tumors 2256159

M Mary Priyanka Udumula (Henry Ford Health System+ Michigan State University) A Anjaly KM (Henry Ford Health) N Nematullah Mohammad (Henry Ford Health) M Miriana Hijaz (Henry Ford Health) S Shailendra Giri E Eduardo Nunes Chini (Mayo Clinic and Foundation, Jacksonville) H Heather Marie Gibson (Wayne State University) R Ramandeep Rattan

Abstract

Abstract Introduction Ovarian cancer (OvCa) remains the most lethal gynecologic malignancy, with older women experiencing the poorest outcomes. Aging profoundly remodels the ovarian tumor immune microenvironment (TME), promoting regulatory T cell (Treg) mediated immune evasion; however, the underlying metabolic mechanisms remain unclear. Methods Using young (3-month) and aged (22-month) female mice injected intraperitoneally with ID8p53⁻/⁻ OvCa cells, we investigated how age associated metabolic reprogramming influences tumor immunity Results Aged OvCa bearing mice exhibited accelerated tumor progression, reduced survival (median 54 vs. 72 days), decreased CD4+ and CD8+ T cells, and an expanded Treg population. Metabolomic profiling revealed increased succinate accumulation in ascites, tumor tissue, and serum of aged mice and elderly OvCa patients. Exogenous succinate enhanced CCR4+FOXP3+ Treg frequency and upregulated IL-10 and TGF-β secretion. Elevated levels of CCL22, a CCR4 ligand, were also detected in ascites from aged mice and patients, suggesting a chemokine-driven reinforcement of Treg recruitment. PBMCs from aged patients displayed an OXPHOS-reprogrammed CCR4+FOXP3+ Treg subset with heightened suppressive capacity, markedly inhibiting CD4+ and CD8+ effector cytotoxicity. Treatment with AA6, an α-ketoglutarate dehydrogenase inhibitor that blocks succinate synthesis, reduced CCR4+FOXP3+ Treg accumulation, restored effector T-cell function, and significantly prolonged survival in aged OvCa-bearing mice. Conclusion Together, these findings reveal a novel succinate—CCR4 metabolic—chemokine axis that drives Treg mediated immunosuppression in aged OvCa. Targeting this pathway offers a promising strategy to restore anti-tumor immunity and overcome age-related immunotherapy resistance in ovarian cancer. Funding Source N/A Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)

Article Details

Volume / Issue Vol. 215, Issue Supplement_1
Published August 01, 2026
ISSN 0022-1767
Publisher American Association of Immunologists

Authors (8)

M

Mary Priyanka Udumula

Henry Ford Health System+ Michigan State University

A

Anjaly KM

Henry Ford Health

N

Nematullah Mohammad

Henry Ford Health

M

Miriana Hijaz

Henry Ford Health

S

Shailendra Giri

E

Eduardo Nunes Chini

Mayo Clinic and Foundation, Jacksonville

H

Heather Marie Gibson

Wayne State University

R

Ramandeep Rattan